204 related articles for article (PubMed ID: 30584995)
1. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.
Kim JW; Kim JG; Kang BW; Chung IJ; Hong YS; Kim TY; Song HS; Lee KH; Zang DY; Ko YH; Song EK; Baek JH; Koo DH; Oh SY; Cho H; Lee KW
Cancer Res Treat; 2019 Jan; 51(1):223-239. PubMed ID: 30584995
[TBL] [Abstract][Full Text] [Related]
2. Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study.
Mayrbäurl B; Giesinger JM; Burgstaller S; Piringer G; Holzner B; Thaler J
Support Care Cancer; 2016 Feb; 24(2):667-674. PubMed ID: 26123602
[TBL] [Abstract][Full Text] [Related]
3. Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.
Creutzfeldt A; Suling A; Oechsle K; Mehnert A; Atanackovic D; Kripp M; Arnold D; Stein A; Quidde J
BMC Palliat Care; 2016 Mar; 15():25. PubMed ID: 26928745
[TBL] [Abstract][Full Text] [Related]
4. Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy.
Park SH; Cho MS; Kim YS; Hong J; Nam E; Park J; Cho EK; Shin DB; Lee JH; Lee WK
Qual Life Res; 2008 Mar; 17(2):207-14. PubMed ID: 18224458
[TBL] [Abstract][Full Text] [Related]
5. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Kripp M; Al-Batran SE; Rosowski J; Pauligk C; Homann N; Hartmann JT; Moehler M; Hofheinz RD
Gastric Cancer; 2014 Jan; 17(1):181-7. PubMed ID: 23455717
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
7. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
Guntinas-Lichius O; Rühlow S; Veelken F; Klussmann JP
J Cancer Res Clin Oncol; 2009 Jul; 135(7):901-8. PubMed ID: 19085003
[TBL] [Abstract][Full Text] [Related]
8. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
9. EORTC QLQ-C15-PAL quality of life score as a prognostic indicator of survival in patients with far advanced cancer.
Lee YJ; Suh SY; Choi YS; Shim JY; Seo AR; Choi SE; Ahn HY; Yim E
Support Care Cancer; 2014 Jul; 22(7):1941-8. PubMed ID: 24577883
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
11. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
[TBL] [Abstract][Full Text] [Related]
12. Changes in quality of life during palliative chemotherapy for solid cancer.
Bang SM; Park SH; Kang HG; Jue JI; Cho IH; Yun YH; Cho EK; Shin DB; Lee JH
Support Care Cancer; 2005 Jul; 13(7):515-21. PubMed ID: 15678347
[TBL] [Abstract][Full Text] [Related]
13. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Curran D; Pozzo C; Zaluski J; Dank M; Barone C; Valvere V; Yalcin S; Peschel C; Wenczl M; Goker E; Bugat R
Qual Life Res; 2009 Sep; 18(7):853-61. PubMed ID: 19568958
[TBL] [Abstract][Full Text] [Related]
14. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
von Plessen C; Bergman B; Andresen O; Bremnes RM; Sundstrom S; Gilleryd M; Stephens R; Vilsvik J; Aasebo U; Sorenson S
Br J Cancer; 2006 Oct; 95(8):966-73. PubMed ID: 17047644
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
[TBL] [Abstract][Full Text] [Related]
17. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
Chau I; Fuchs CS; Ohtsu A; Barzi A; Liepa AM; Cui ZL; Hsu Y; Al-Batran SE
Eur J Cancer; 2019 Jan; 107():115-123. PubMed ID: 30557792
[TBL] [Abstract][Full Text] [Related]
18. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
20. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]